Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.00 (0.00%)
Close on Nov 18, 2026Market cap $28.91MP/E –Yield –
Aytu BioPharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Aytu BioPharma's revenue for the twelve months ending Jun 30, 2026 was $57.57M, down 13.3% year over year. For fiscal 2026 it was $57.57M, down 13.3% from the year before. Over ten years it grew 36.5% a year on average. The highest annual figure on record is $107.40M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $57.57M | -13.3% |
| FY2025 | Jun 30, 2025 | $66.38M | +1.8% |
| FY2024 | Jun 30, 2024 | $65.18M | -39.3% |
| FY2023 | Jun 30, 2023 | $107.40M | +11.1% |
| FY2022 | Jun 30, 2022 | $96.67M | +47.3% |
| FY2021 | Jun 30, 2021 | $65.63M | +137.5% |
| FY2020 | Jun 30, 2020 | $27.63M | +277.5% |
| FY2019 | Jun 30, 2019 | $7.32M | +100.0% |
| FY2018 | Jun 30, 2018 | $3.66M | +13.6% |
| FY2017 | Jun 30, 2017 | $3.22M | +25.7% |
| FY2016 | Jun 30, 2016 | $2.56M | +878.8% |
| FY2015 | Jun 30, 2015 | $261.78K | +14859.0% |
| FY2013 | Aug 31, 2013 | $1.75K | 0.0% |
| FY2012 | Aug 31, 2012 | $1.75K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $16.11M | +6.4% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $12.41M | -32.7% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $15.17M | -6.5% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $13.89M | -16.2% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $15.14M | +3.7% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $18.45M | +31.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $16.22M | -13.5% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $16.57M | -7.0% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $14.59M | -52.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $14.03M | -38.3% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $18.75M | -28.7% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $17.82M | -35.6% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $30.73M | +12.0% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $22.73M | -6.1% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $26.28M | +13.6% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $27.66M | +26.3% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $27.45M | +16.9% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $24.20M | +79.5% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $23.13M | +52.7% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $21.90M | +62.0% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $23.48M | +58.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $13.48M | +65.3% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $15.15M | +377.1% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $13.52M | +839.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $14.86M | +766.2% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $8.16M | +243.0% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $3.18M | +76.9% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $1.44M | +0.6% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $1.72M | +85.5% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $2.38M | +291.4% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $1.80M | +70.8% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.43M | +33.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $925.13K | +10.7% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $607.47K | -32.0% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $1.05M | +32.4% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $1.08M | +54.2% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $835.89K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $893.55K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $794.17K | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $697.98K | – |
See a number that looks wrong?